

**DATE:** July 29, 1997

**MEMORANDUM**

**SUBJECT:** CHLORPYRIFOS -Report of the Risk Assessment Review Committee.

**FROM:** Jess Rowland, M.S.  
Executive Secretary,  
Risk Assessment Review Committee,  
Health Effects Division (7509C)

**THROUGH:** Michael Metzger, Ph.D.  
Chairman, Risk Assessment Review Committee  
Health Effects Division (7509C)

**TO:** Karen Whitby, Ph.D.  
Chief, Risk Characterization and Analysis Branch  
Health Effects Division (7509C)  
and  
Kathy Monk  
Chief, Reregistration Branch-2,  
Special Review and Reregistration Division (7508W)

The Health Effects Division (HED) Risk Assessment Review Committee (RARC) met on July 29, 1997 to review HED's chapter of the *Reregistration Eligibility Decision Document (RED) for Chlorpyrifos* (PC Code: 059101; Case #:0100). The Committees recommendations and conclusions are attached.

## REPORT OF THE RISK ASSESSMENT REVIEW COMMITTEE

The Health Effects Division (HED) Risk Assessment Review Committee met on July 29, 1997 to review HED's chapter of the *Reregistration Eligibility Decision Document (RED)* for *Chlorpyrifos* (PC Code: 059101; Case #:0100).

### The Committee's recommendations are as follows:

Need to fully characterize as to why there is no risk either from surface or drinking water by further evaluation of the physical chemical properties, monitoring data, leaching potential, etc.

Need to characterize the toxicity endpoints selected for hazard identification. Rationales used in selecting the doses and endpoints for the acute dietary and chronic dietary (RfD) as well as occupational and residential exposure risk assessments should be included.

The dose used to establish the RfD is different from that of the FAO/WHO; a rationale should be presented explaining the differences. This will indicate the differences in the approaches taken by the Agency vs. WHO.

A discussion on not requiring inhalation risk assessment should be presented, although, inhalation risk is not expected to be a concern.

Need to be more transparent in the Monte Carlo risk assessment used. Need more explanation on the acute dietary risk assessment, the MOEs and percentiles. Explain the difference between the MOEs obtained from the DRES runs and Monte Carlo analysis.

Need a rationale for the 1% dermal absorption (DA) used. This should be mentioned in the tables where DA was used in MOE calculations.

Summarize the human incidence data (Section D) and domestic animal incident data (Section E) with the salient facts to characterize the risk but include the details as a separate document.

Present the MOEs in whole numbers and not in fractions.

Need a rationale for not requiring an extra UF for risk assessments for infants and children.

Need a rationale for the 15 aggregate risk assessment conducted for the various exposure scenarios; why those scenarios were selected (page 167).

Tolerance reassessment summary table on page 173s need to be modified; not to include 409.

SRRD will provide a specific format for "better flow" of the dietary portion of the document. Also, a "summary" should be written for each section of the document."

Possibly write an addendum to address the mosquitocide use.

RARC Members@:

Kathryn Boyle

\_\_\_\_\_

Ed Brandt

\_\_\_\_\_

Bill Burnam

\_\_\_\_\_

Paula Deschamp

\_\_\_\_\_

Roger Gardner

\_\_\_\_\_

Stephanie Irene

\_\_\_\_\_

Tina Levine

\_\_\_\_\_

Barbara Madden

\_\_\_\_\_

Tim McMahon

\_\_\_\_\_

Mike Metzger

\_\_\_\_\_

David Miller r

\_\_\_\_\_

Henry Nelson

\_\_\_\_\_

Al Nielsen

\_\_\_\_\_

Margaret Rice

\_\_\_\_\_

Jess Rowland

\_\_\_\_\_

Christina Scheltema

\_\_\_\_\_

Jane Smith

\_\_\_\_\_

---

@ = Signature indicates concurrence with science assessment review process unless otherwise stated.